Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138889 | 0.89 | NPC1 (0.34) | SMN1; SMN2NPC1RAB9ASLC40A1 | |
| SCHEMBL4125428 | 0.87 | MAPT (0.38) | HIF1ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL4129846 | 0.81 | ALDH1A1 (0.33) | MAPTLMNAALDH1A1 | |
| SCHEMBL3651371 | 0.81 | CTSA (0.33) | ALDH1A1 | |
| SCHEMBL4125990 | 0.81 | MAPT (0.38) | HIF1ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL3807956 | 0.80 | MAPT (0.36) | HIF1ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL4135584 | 0.79 | GAA (0.39) | HIF1ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL4131864 | 0.79 | MAPT (0.35) | HIF1ASMN1; SMN2MAPTTP53LMNA | |
| SCHEMBL4131691 | 0.78 | MAPT (0.41) | SMN1; SMN2MAPTTP53LMNAGAA | |
| SCHEMBL4120354 | 0.78 | CTSA (0.35) | SMN1; SMN2MAPTTP53LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | HIF1A 3779/4885SMN1; SMN2 4327/4885NPC1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.